Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Se Hoon Lee

Showing results (91-100 of 513) with videos related to

Pageof 52
Sort By:
Expert Opinion on Pharmacotherapy|August 2, 2020
Evaluating entrectinib as a treatment option for non-small cell lung cancerJiyun Lee, Sehhoon Park, Hyun Ae Jung, et al.
Scientific Reports|October 25, 2023
Comparative analysis of batch correction methods for FDG PET/CT using metabolic radiogenomic data of lung cancer patientsHyunjong Lee, Sujin Seo, Sungho Won, et al.
Investigational New Drugs|April 6, 2016
AZD9291 overcomes T790 M-mediated resistance through degradation of EGFR(L858R/T790M) in non-small cell lung cancer cellsBo Mi Ku, Yeon-Hee Bae, Jiae Koh, et al.
The Journal of Urology|May 23, 2015
The Impact of PBRM1 Expression as a Prognostic and Predictive Marker in Metastatic Renal Cell CarcinomaJi-Yeon Kim, Se-Hoon Lee, Kyung Chul Moon, et al.
Frontiers in Oncology|June 4, 2026
Paired ctDNA analysis reveals diverse resistance mechanisms to mobocertinib in EGFR exon 20 insertion NSCLCJinyong Kim, Geun-Ho Park, Sehhoon Park, et al.
Cancer Research and Treatment|July 1, 2020
EGFR C797S as a Resistance Mechanism of Lazertinib in Non-small Cell Lung Cancer with EGFR T790M MutationSehhoon Park, Bo Mi Ku, Hyun Ae Jung, et al.
Cancer Research and Treatment|February 13, 2015
Cisplatin-Based Chemotherapy Is a Strong Risk Factor for Thromboembolic Events in Small-Cell Lung CancerYun-Gyoo Lee, Eunyoung Lee, Inho Kim, et al.
Scientific Reports|September 10, 2024
Dissecting transcriptome signals of anti-PD-1 response in lung adenocarcinomaKyeongmi Lee, Honghui Cha, Jaewon Kim, et al.
European Journal of Cancer (Oxford, England : 1990)|May 7, 2020
Outstanding clinical efficacy of PD-1/PD-L1 inhibitors for pulmonary pleomorphic carcinomaJiyun Lee, Yoon La Choi, Hyun Ae Jung, et al.
European Journal of Cancer (Oxford, England : 1990)|July 12, 2025
Prospective investigation of biomarker and resistance mechanism using longitudinal cell-free NGS in non-small cell lung cancer with EGFR exon 20 insertion treated with amivantamabGeun-Ho Park, Sehhoon Park, Hyemin Kim, et al.
Pageof 52

Showing results (91-100 of 513) with videos related to

Sort By:
Pageof 52
Expert Opinion on Pharmacotherapy|August 2, 2020
Evaluating entrectinib as a treatment option for non-small cell lung cancerJiyun Lee, Sehhoon Park, Hyun Ae Jung, et al.
Scientific Reports|October 25, 2023
Comparative analysis of batch correction methods for FDG PET/CT using metabolic radiogenomic data of lung cancer patientsHyunjong Lee, Sujin Seo, Sungho Won, et al.
Investigational New Drugs|April 6, 2016
AZD9291 overcomes T790 M-mediated resistance through degradation of EGFR(L858R/T790M) in non-small cell lung cancer cellsBo Mi Ku, Yeon-Hee Bae, Jiae Koh, et al.
The Journal of Urology|May 23, 2015
The Impact of PBRM1 Expression as a Prognostic and Predictive Marker in Metastatic Renal Cell CarcinomaJi-Yeon Kim, Se-Hoon Lee, Kyung Chul Moon, et al.
Frontiers in Oncology|June 4, 2026
Paired ctDNA analysis reveals diverse resistance mechanisms to mobocertinib in EGFR exon 20 insertion NSCLCJinyong Kim, Geun-Ho Park, Sehhoon Park, et al.
Cancer Research and Treatment|July 1, 2020
EGFR C797S as a Resistance Mechanism of Lazertinib in Non-small Cell Lung Cancer with EGFR T790M MutationSehhoon Park, Bo Mi Ku, Hyun Ae Jung, et al.
Cancer Research and Treatment|February 13, 2015
Cisplatin-Based Chemotherapy Is a Strong Risk Factor for Thromboembolic Events in Small-Cell Lung CancerYun-Gyoo Lee, Eunyoung Lee, Inho Kim, et al.
Scientific Reports|September 10, 2024
Dissecting transcriptome signals of anti-PD-1 response in lung adenocarcinomaKyeongmi Lee, Honghui Cha, Jaewon Kim, et al.
European Journal of Cancer (Oxford, England : 1990)|May 7, 2020
Outstanding clinical efficacy of PD-1/PD-L1 inhibitors for pulmonary pleomorphic carcinomaJiyun Lee, Yoon La Choi, Hyun Ae Jung, et al.
European Journal of Cancer (Oxford, England : 1990)|July 12, 2025
Prospective investigation of biomarker and resistance mechanism using longitudinal cell-free NGS in non-small cell lung cancer with EGFR exon 20 insertion treated with amivantamabGeun-Ho Park, Sehhoon Park, Hyemin Kim, et al.
Pageof 52